Literature DB >> 15902472

Piboserod (SB 207266), a selective 5-HT4 receptor antagonist, reduces serotonin potentiation of neurally-mediated contractile responses of human detrusor muscle.

B Darblade1, D Behr-Roussel, D Gorny, T Lebret, G Benoit, J-P Hieble, D Brooks, L Alexandre, F Giuliano.   

Abstract

The aim of this study is to evaluate the potency of piboserod (SB 207266), a selective 5-HT(4) receptor antagonist, at inhibiting the 5-HT(4)-mediated potentiating effect of serotonin (5-HT) on the neurally-mediated contractile responses of human detrusor strips to electrical field stimulations (EFS). Strips of human detrusor muscle were mounted in Krebs-HEPES buffer under a resting tension of 500 mg and EFS (20 Hz, 1 ms duration at 300 mA for 5 s) was applied continuously at 1 min intervals. After stabilization of the EFS-induced contractions, concentration-response curves to 5-HT (0.1 nM-100 microM) were constructed in the absence or presence of 1 or 100 nM of piboserod. The experiments were performed in the presence of methysergide (1 microM) and ondansetron (3 microM) to block 5HT(1)/5HT(2) and 5-HT(3) receptors, respectively. 5-HT potentiated the contractile responses to EFS of human bladder strips in a concentration-dependent manner, with a maximum mean of 60.0+/-19.9% of the basal EFS-evoked contractions. Piboserod did not modify the basal contractions but concentration-dependently antagonized the ability of 5-HT to enhance bladder strip contractions to EFS. In presence of 1 and 100 nM of piboserod, the maximal 5-HT-induced potentiations were reduced to 45.0+/-7.9 and 38.7+/-8.7%, respectively. A mean apparent antagonist dissociation constant value (K(B)) of 0.56+/-0.09 nM was determined. These data show the ability of piboserod to antagonize with high potency the enhancing properties of 5-HT on neurally-mediated contractions of isolated human bladder strips. Therefore, the 5-HT(4) receptor might represent an attractive pharmacological target for the treatment of overactive bladder.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15902472     DOI: 10.1007/s00345-005-0499-z

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  16 in total

1.  Selective and functional 5-hydroxytryptamine4 receptor antagonism by SB 207266.

Authors:  K A Wardle; S Bingham; E S Ellis; L M Gaster; B Rushant; M I Smith; G J Sanger
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

2.  5-HT4 receptor agonists and bladder disorders.

Authors:  M Tonini; S M Candura
Journal:  Trends Pharmacol Sci       Date:  1996-09       Impact factor: 14.819

3.  Some quantitative uses of drug antagonists. 1958.

Authors:  O Arunlakshana; H O Schild
Journal:  Br J Pharmacol       Date:  1997-02       Impact factor: 8.739

4.  Pharmacology of electrically evoked contractions of human bladder [proceedings].

Authors:  J R Hindmarsh; O A Idowu; W K Yeates; M A Zar
Journal:  Br J Pharmacol       Date:  1977-09       Impact factor: 8.739

5.  N-[(1-butyl-4-piperidinyl)methyl]-3,4dihydro-2H-[1,3]oxazino[3,2- a]indole10-carboxamide hydrochloride: the first potent and selective 5-HT4 receptor antagonist amide with oral activity.

Authors:  L M Gaster; G F Joiner; F D King; P A Wyman; J M Sutton; S Bingham; E S Ellis; G J Sanger; K A Wardle
Journal:  J Med Chem       Date:  1995-11-24       Impact factor: 7.446

6.  Urinary disorders associated with cisapride. Adverse Drug Reactions Advisory Committee.

Authors:  I W Boyd; A P Rohan
Journal:  Med J Aust       Date:  1994-05-02       Impact factor: 7.738

7.  Neural 5-HT4 receptors in the human isolated detrusor muscle: effects of indole, benzimidazolone and substituted benzamide agonists and antagonists.

Authors:  S M Candura; E Messori; G P Franceschetti; G D'Agostino; D Vicini; M Tagliani; M Tonini
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

8.  Pharmacological analysis of 5-hydroxytryptamine effects on electrically stimulated human isolated urinary bladder.

Authors:  M Corsi; C Pietra; G Toson; D Trist; G Tuccitto; W Artibani
Journal:  Br J Pharmacol       Date:  1991-11       Impact factor: 8.739

9.  Treatment with cisapride of the gastrointestinal and urological sequelae of spinal cord transection: case report.

Authors:  M Etienne; M Verlinden; A Brassinne
Journal:  Paraplegia       Date:  1988-06

10.  Characterization of the 5-HT receptor potentiating neuromuscular cholinergic transmission in strips of human isolated detrusor muscle.

Authors:  M Tonini; E Messori; G P Franceschetti; C A Rizzi; A F Castoldi; T Coccini; S M Candura
Journal:  Br J Pharmacol       Date:  1994-09       Impact factor: 8.739

View more
  2 in total

Review 1.  Emerging pharmacological targets in overactive bladder therapy: experimental and clinical evidences.

Authors:  Emilio Sacco; Francesco Pinto; Pierfrancesco Bassi
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2008-01-15

Review 2.  Innovative pharmacotherapies for women with overactive bladder: where are we now and what is in the pipeline?

Authors:  Emilio Sacco; Riccardo Bientinesi
Journal:  Int Urogynecol J       Date:  2014-11-07       Impact factor: 2.894

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.